Literature DB >> 34744356

Detection of c.755T>C; p.L265P/c.751C>T;p.264R/* compound heterozygous MYD88 mutation in a case of Waldenstrom macroglobulinemia.

Arambam Gautam1, Dharambir Kashyap2, Deepesh Lad3, Amanjit Bal2, Reena Das1, Sreejesh Sreedharanunni1.   

Abstract

Entities:  

Year:  2021        PMID： 34744356      PMCID： PMC8523614          DOI： 10.1007/s12288-021-01446-5

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN： 0971-4502            Impact factor:   0.915


× No keyword cloud information.
  5 in total

1.  Oncogenically active MYD88 mutations in human lymphoma.

Authors:  Vu N Ngo; Ryan M Young; Roland Schmitz; Sameer Jhavar; Wenming Xiao; Kian-Huat Lim; Holger Kohlhammer; Weihong Xu; Yandan Yang; Hong Zhao; Arthur L Shaffer; Paul Romesser; George Wright; John Powell; Andreas Rosenwald; Hans Konrad Muller-Hermelink; German Ott; Randy D Gascoyne; Joseph M Connors; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Jan Delabie; Erlend B Smeland; Richard I Fisher; Rita M Braziel; Raymond R Tubbs; J R Cook; Denny D Weisenburger; Wing C Chan; Louis M Staudt
Journal:  Nature       Date:  2010-12-22       Impact factor: 49.962

2.  A novel truncating mutation in MYD88 in a patient with BCG adenitis, neutropenia and delayed umbilical cord separation.

Authors:  Craig D Platt; Fatima Zaman; Jacqueline G Wallace; Michael Seleman; Janet Chou; Nashat Al Sukaiti; Raif S Geha
Journal:  Clin Immunol       Date:  2019-07-10       Impact factor: 3.969

3.  Pyogenic bacterial infections in humans with MyD88 deficiency.

Authors:  Horst von Bernuth; Capucine Picard; Zhongbo Jin; Rungnapa Pankla; Hui Xiao; Cheng-Lung Ku; Maya Chrabieh; Imen Ben Mustapha; Pegah Ghandil; Yildiz Camcioglu; Júlia Vasconcelos; Nicolas Sirvent; Margarida Guedes; Artur Bonito Vitor; María José Herrero-Mata; Juan Ignacio Aróstegui; Carlos Rodrigo; Laia Alsina; Estibaliz Ruiz-Ortiz; Manel Juan; Claudia Fortuny; Jordi Yagüe; Jordi Antón; Mariona Pascal; Huey-Hsuan Chang; Lucile Janniere; Yoann Rose; Ben-Zion Garty; Helen Chapel; Andrew Issekutz; László Maródi; Carlos Rodriguez-Gallego; Jacques Banchereau; Laurent Abel; Xiaoxia Li; Damien Chaussabel; Anne Puel; Jean-Laurent Casanova
Journal:  Science       Date:  2008-08-01       Impact factor: 47.728

4.  MYD88 mutant lymphoplasmacytic lymphoma/Waldenström macroglobulinemia has distinct clinical and pathological features as compared to its mutation negative counterpart.

Authors:  Nikhil Patkar; P G Subramanian; Prashant Deshpande; Kiran Ghodke; Prashant Tembhare; Russel Mascarenhas; Aditi Muranjan; Shruti Chaudhary; Bhausaheb Bagal; Sumeet Gujral; Manju Sengar; Hari Menon
Journal:  Leuk Lymphoma       Date:  2014-08-04

5.  A novel MYD88 mutation, L265RPP, in Waldenström macroglobulinemia activates the NF-κB pathway to upregulate Bcl-xL expression and enhances cell survival.

Authors:  T Nagao; G Oshikawa; S Ishida; H Akiyama; Y Umezawa; A Nogami; T Kurosu; O Miura
Journal:  Blood Cancer J       Date:  2015-05-15       Impact factor: 11.037
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.